Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P.

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic advance for inflammatory bowel disease.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Lynk Pharmaceuticals’ next generation JAK inhibitor, zemprocitinib, has met its primary and secondary trial endpoints during a Phase III study in rheumatoid arthritis. Image credit: one photo via ...

AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer ...